콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

1224551

USP

Docetaxel

United States Pharmacopeia (USP) Reference Standard

동의어(들):

Docetaxel trihydrate

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C43H53NO14 · 3H2O
CAS Number:
148408-66-6
Molecular Weight:
861.93
MDL number:
MFCD26960948
UNSPSC 코드:
41116107
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

docetaxel

제조업체/상표

USP

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

N([C@H]([C@@H](O)C(=O)O[C@H]2C[C@]3([C@H]([C@@H]5[C@]6([C@H](OC6)C[C@@H]([C@]5(C(=O)[C@@H](C(=C2C)C3(C)C)O)C)O)OC(=O)C)OC(=O)c4ccccc4)O)c1ccccc1)C(=O)OC(C)(C)C.O.O.O

InChI

1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1

InChI key

XCDIRYDKECHIPE-QHEQPUDQSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Docetaxel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Also, for use with USP monograph such as Docetaxel Injection

분석 메모

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

기타 정보

Sales restrictions may apply.

픽토그램

Health hazardExclamation mark
GHS08,GHS07

신호어

Danger

유해 및 위험 성명서

H319,H360F

Hazard Classifications

Eye Irrit. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Monisha Sudarshan et al.
Annals of surgical oncology, 22(1), 324-330 (2014-07-16)
We have previously identified Docetaxel, Cisplatin, and 5FU (DCF) as a safe, tolerable, and effective regimen in the neoadjuvant setting for locally advanced adenocarcinoma (ADC) of the esophagus and esophagogastric junction (EGJ). We hypothesized that DCF combined with enhanced surgical
Alice Dragomir et al.
BMC health services research, 14, 252-252 (2014-06-15)
For Canadian men, prostate cancer (PCa) is the most common cancer and the 3rd leading cause of cancer mortality. Men dying of PCa do so after failing castration. The management of metastatic castration-resistant prostate cancer (mCRPC) is complex and the
Fred Saad et al.
European urology, 67(2), 223-230 (2014-08-31)
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA)
Michel D Wissing et al.
Oncotarget, 5(17), 7357-7367 (2014-10-04)
Novel biomarkers predicting prostate cancer (PCa) aggressiveness and docetaxel therapy response of PCa patients are needed. In this study the correlation between nuclear Eg5-expression, PCa docetaxel response and PCa aggressiveness was assessed. Immunohistochemical staining for nuclear Eg5 was performed on
Josien C Haan et al.
Nature communications, 5, 5457-5457 (2014-11-15)
Response to drug therapy in individual colorectal cancer (CRC) patients is associated with tumour biology. Here we describe the genomic landscape of tumour samples of a homogeneous well-annotated series of patients with metastatic CRC (mCRC) of two phase III clinical
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.